SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

SPERMWHALE has emerged as a trending meme coin, triggering polarized community debate between retail investors chasing rapid momentum and skeptics warning of a potential pump-and-dump scheme. While some traders tout its chart structure and low entry point as evidence of growth potential, critics highlight concentrated ownership among top holders and the lack of fundamental utility as major red flags.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

The Fundrise Innovation Fund is experiencing extreme volatility and rapid price appreciation following its NYSE listing, with retail investors and traders closely monitoring its high-profile private equity holdings like SpaceX and Anthropic. While some in the community are bullish on the long-term potential of the fund's portfolio, others are debating the massive premium over net asset value and the impact of the six-month lockup period restricting many early shareholders.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is experiencing significant market interest and elevated trading volume as investors react to unconfirmed reports of a potential acquisition by a large-cap biopharmaceutical company. Community sentiment is deeply divided between long-term shareholders holding out for a lucrative buyout and skeptical traders who view the price action as speculative volatility.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean (RIG) is currently capturing significant investor attention due to its pending merger with Valaris, which aims to create an offshore drilling powerhouse with improved pricing power and a massive contract backlog. The market is also heavily focused on RIG's operational turnaround and debt reduction efforts, while community discussions remain intensely volatile as traders weigh the impact of potential geopolitical instability in energy-rich regions against the stock's recent price momentum.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is surging as investors closely monitor earnings and guidance, with the community highly focused on potential new contract awards and the company's long-term growth in the space infrastructure sector. Shareholders are expressing strong bullish sentiment, betting on significant revenue expansion and future moon mission catalysts, while retail traders remain sharply divided over the stock's valuation and volatility.

WeRide, Inc. operates as an investment holding company. It engages in the sale of autonomous driving vehicles, primarily including robobuses, robotaxis, robosweepers and related sensor suites. The company was founded by Tony Xu Han and Yan Li in February 2017 and is headquartered in Guangzhou, China.

WeRide Inc. - ADR

WeRide (WRD) is trending following multiple operational updates, including the rollout of fully driverless commercial robotaxi services in the Middle East through an Uber partnership and successful autonomous driving competitions in China. While investors are actively debating the company's valuation gap compared to sector peers and its long-term scaling strategy, sentiment is heavily influenced by institutional accumulation, including increased holdings by ARK Invest, contrasted against concerns regarding the CEO's limited communication and the stock's recent volatility.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

The S&P 500 is experiencing heightened volatility as market participants weigh geopolitical instability in the Middle East against conflicting reports of potential diplomatic breakthroughs. Investors are actively debating the credibility of recent peace-related headlines, with many expressing skepticism toward government communication while remaining focused on the subsequent impact on oil prices and overall market direction.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

FuboTV is experiencing heightened volatility and intense community debate as shareholders brace for a scheduled 1-for-12 reverse stock split. While some investors are betting on a post-split turnaround driven by a reduced float and potential short-squeeze dynamics, many others are expressing deep frustration over prolonged share price depreciation and the lack of transparent management communication.

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

Cingulate Inc

Cingulate is experiencing a surge in interest and volatility as investors position themselves for an upcoming patent approval and the May PDUFA date for its ADHD treatment candidate. The community is actively debating the potential for a buyout, while some participants express caution regarding potential share dilution and manufacturing scrutiny by the FDA.

WorldFinancial

World Liberty Financial is facing increased volatility and investor scrutiny following a Congressional investigation into its foreign ownership and potential conflicts of interest. While some community members are holding for long-term integration with real-world assets, others are expressing heavy skepticism, frequently labeling the project a speculative play or questioning the transparency of its leadership.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tarsus Pharmaceuticals (NASDAQ:TARS) CEO Sells $761,676.24 in Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) CEO Bobak Azamian sold 10,972 shares of the firm's stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $69.42, for a total value of $761,676.24. Following the completion of the transaction, the...

Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Jeffrey Farrow Sells 2,111 Shares

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) insider Jeffrey Farrow sold 2,111 shares of the stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $69.42, for a total transaction of $146,545.62. Following the transaction, the insider owned 47,635...

Insider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Sells 2,186 Shares of Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) insider Jeffrey Farrow sold 2,186 shares of the business's stock in a transaction on Thursday, March 19th. The shares were sold at an average price of $67.00, for a total transaction of $146,462.00. Following the transaction, the insider...

Insider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Sells 2,133 Shares of Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) insider Jeffrey Farrow sold 2,133 shares of the stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $68.71, for a total transaction of $146,558.43. Following the completion of the...

Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Elizabeth Yeu Lin Sells 390 Shares

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) insider Elizabeth Yeu Lin sold 390 shares of the firm's stock in a transaction on Thursday, March 19th. The shares were sold at an average price of $67.00, for a total value of $26,130.00. Following the sale, the insider directly owned...

Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Elizabeth Yeu Lin Sells 375 Shares

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) insider Elizabeth Yeu Lin sold 375 shares of the business's stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $69.42, for a total transaction of $26,032.50. Following the transaction...

Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Sells $26,041.09 in Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) insider Elizabeth Yeu Lin sold 379 shares of the company's stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $68.71, for a total transaction of $26,041.09. Following the completion of the...

Insider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Sells 4,029 Shares of Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) insider Dianne Whitfield sold 4,029 shares of the business's stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $69.42, for a total value of $279,693.18. Following the transaction, the insider owned...

Dianne Whitfield Sells 4,071 Shares of Tarsus Pharmaceuticals (NASDAQ:TARS) Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) insider Dianne Whitfield sold 4,071 shares of the stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $68.71, for a total value of $279,718.41. Following the transaction, the insider owned 39,202...

Tarsus Pharmaceuticals (NASDAQ:TARS) General Counsel Sells $283,428.75 in Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) General Counsel Bryan Wahl sold 4,125 shares of the stock in a transaction dated Wednesday, March 18th. The shares were sold at an average price of $68.71, for a total value of $283,428.75. Following the transaction, the general counsel...

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. It is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.33	--	--	N/A
Q4 '25	-$0.09	-$0.20	-115.11%	MISSED
Q3 '25	-$0.35	-$0.30	14.14%	BEAT
Q2 '25	-$0.38	-$0.48	-26.79%	MISSED
Q1 '25	-$0.73	-$0.64	12.31%	BEAT

TARS
Tarsus Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest TARS News

TARSTarsus Pharmaceuticals Inc